Accessibility Menu
Oncolytics Biotech logo

Oncolytics Biotech(TSX) ONC

This security has been delisted. This page is retained for historical reference.

Oncolytics Biotech last closing stock price
MetricPriceDate
Last closeCAD 1.422025-08-22
Oncolytics Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.7%CAD 1.492025-08-15
1 month-11.8%CAD 1.612025-07-23
3 month+158.18%CAD 0.552025-05-23
Year to date+6.77%CAD 1.332024-12-31
1 year+9.23%CAD 1.302024-08-22
3 year-21.11%CAD 1.802022-08-23
5 year-35.45%CAD 2.202020-08-21
Since inception-90.04%CAD 14.251999-11-08

ONC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ONC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

5214.36%

Return on Capital

-496.41%

Return on Assets

-435.28%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-CA$394.00K

Operating Income

-CA$31.04M

EBITDA

-CA$30.65M

Operating Cash Flow

-CA$24.65M

Capital Expenditure

-CA$38.00K

Free Cash Flow

-CA$24.69M

Cash & ST Invst.

CA$14.63M

Total Debt

CA$888.00K

Oncolytics Biotech Performance Analysis

Oncolytics Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
Oncolytics Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31N/A
Q22025-06-30N/A
Oncolytics Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.43-12.9%
20232023-12-31CAD -0.41-4.1%
20242024-12-31CAD -0.41-0.5%
20252025-12-31CAD -0.422.7%
Oncolytics Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30-25.8%
Q42024-12-3116.7%
Q12025-03-3121.0%
Q22025-06-3014.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$94.00K

+4.1%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

28

N/A

Net Income

-CA$6.17M

+15.0%

EBITDA

-CA$5.61M

+28.9%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

CA$14.63M

-41.1%

Total Debt

CA$888.00K

-20.4%

Accounts Receivable

CA$72.00K

-95.4%

Inventory

CA$0.00

N/A

Long Term Debt

CA$597.00K

-33.0%

Short Term Debt

CA$582.00K

+158.7%

Return on Assets

-4.35%

N/A

Return on Invested Capital

-12.96%

N/A

Free Cash Flow

-CA$5.47M

-78348.5%

Operating Cash Flow

-CA$5.47M

-80131.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IGX.TOIntelGenx Technologies Corp.
CA$0.24+17.07%
AEZS.TOAeterna Zentaris Inc.
CA$8.29+8.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$114.92+0.06%
NVDANvidia
$218.99-0.00%
TTDThe Trade Desk
$17.67-0.07%
SOUNSoundHound AI
$7.08+0.10%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.